Rutgers Cancer Institute | Strategic Alliance Partners

October 13, 2023

RWJBarnabas Health, together with Rutgers Cancer Institute of New Jersey, has been named among Becker’s Hospital Review’s 100 Hospitals and Health Systems with Great Oncology Programs for 2023.

September 28, 2023

Renee Kurz, DNP, FNP-BC, AOCNP, discusses social determinants of health that can contribute to disparities in cancer care, highlighting examples seen throughout New Jersey that emphasize the need for further investigation into this landscape.

September 21, 2023

The incidence of multiple myeloma, a rare and incurable cancer of a person’s plasma cells that fight infection and disease, is more than two times higher in Black people compared to white people according to the American Cancer Society’s 2022-2024 Cancer Facts & Figures for African American/Black People.

September 06, 2023

Howard S. Hochster, MD, discusses data from the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care in metastatic colorectal cancer.

September 01, 2023

Sanjay Goel, MD, MS, discusses the safety profile of the TKI tinengotinib as a monotherapy and in combination with chemotherapy in patients with solid tumors.

August 30, 2023

Sanjay Goel, MD, MS, discusses the mechanism of action of tinengotinib and the efficacy of this agent in patients with cholangiocarcinoma.

August 07, 2023

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

August 04, 2023

Grants totaling $1.5 million have been awarded by the New Jersey Commission on Cancer Research to several investigators at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health.

July 31, 2023

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

July 30, 2023

Christina Glytsou, PhD, has received $600,000 over a three-year period from The V Foundation for Cancer Research, a premier cancer research charity, to support her research on mitochondrial dynamics adaptations in drug-resistant acute myeloid leukemia.

July 27, 2023

Sarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.

July 26, 2023

Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has treated its first patient using genetically modified T-cells that were manufactured in its own state-of-the-art Good Manufacturing Practices facility, a fully commissioned clean space for manufacturing of viral vectors and cell products for human administration.

July 24, 2023

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

July 24, 2023

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 17, 2023

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

July 17, 2023

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

July 10, 2023

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 10, 2023

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

July 03, 2023

A brief review of data behind lisocabtagene maraleucel and its role as CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

July 03, 2023

Shared insight on the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, with a focus on axicabtagene ciloleucel.